STAAR Surgical Collamer(R) Accommodating Study Team Reports First Phase Assessments at AAO

MONROVIA, Calif., Oct. 26 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA - News), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products today reported that the Collamer Accommodating Study Team (CAST) formed by the company in late 2008 has provided very promising initial patient vision assessments from the first phase of the project. The CAST is comprised of eight prominent cataract/refractive surgeons from across the United States who since June 2009 have implanted more than 300 eyes with the STAAR nanoFLEX intraocular lens (IOL) for the treatment of cataracts. The purpose of the CAST first phase is to evaluate the accommodating properties of the current nanoFLEX IOL to establish a baseline for future phases. Accommodating IOLs are designed to allow patients to see well at all distances, including enabling the patient to experience improved near and intermediate vision, thus reducing or eliminating the effects of presbyopia. Presbyopia is the loss of the ability to focus on objects at near and intermediate distances and is caused by the loss of elasticity of the crystalline lens after the age 45. Presbyopia is typically corrected with the use of reading glasses or corrective lenses. With standard IOLs cataract patients frequently find a need for reading glasses particularly in low light environments. Near vision is the vision needed to read a book or a menu in dim light. Near vision testing is typically performed at a distance of approximately 40cm or 15.75 inches, while inte...
Click here to read the whole Article (external link)

STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

Q3 2009 STAAR Surgical Earnings Release - After Market Close

Earnings Announcements for Monday, November 2CompanySymbolTimeConferenceCall1ST CONSTITUTION BANCORPFCCYBefore Market OpenAAONAAONBefore Market OpenABSOLUTE SOFTWARE CORPABT.TO4:00 pm ETAdministaffASFBefore Market OpenListenAlbany International CorpAINAfter Market CloseAlexander'sALXBefore Market OpenALLGREEN PROPERTIES LTDA16.SITime Not SuppliedALLIANCE DISTRS HLDG INCADTR.PKBefore Market OpenALTRA HOLDINGS INCAIMCAfter Market CloseAmerican Physicians Service GroupAMPHAfter Market CloseAMERIGO RESOURCES LTDARG.TOBefore Market OpenAnadarko Petroleum CorporationAPCAfter Market CloseListenAnglogold Ashanti LimitedAUTime Not SuppliedAPPLIED NANOTECH HOLDINGS INCAPNT.OBTime Not SuppliedArgo Group International Holdings, Ltd.AGIIAfter Market CloseListenArray BioPharma Inc.ARRYAfter Market CloseListenAss...
Click here to read the whole Article (external link)

STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call

MONROVIA, Calif., Oct. 27 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA - News) today announced that it will release financial results for the third quarter ended September 30, 2009 on Monday, November 2, 2009 after the market close. The Company will host a conference call and webcast on Tuesday, November 3, 2009 at 10:00 a.m. Eastern / 7:00 a.m. Pacific to discuss the Company's third quarter results and current corporate developments. The timing of the release and call results from management's schedule and recent invitation to present at the Oppenheimer & Co. conference on Wednesday, November 4. The dial-in number for the conference call is 877-941-2927 for domestic participants and 480-629-9725 for international participants. A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4169709#. To access the live webcast of the call, go to STAAR's website at www.staar.com. An archived webcast will also be available at ...
Click here to read the whole Article (external link)

STAAR Surgical Earnings Call scheduled for 10:00 am ET today

Call DetailsSTAAR Surgical Earnings Conference Call (Q3 2009)Tue, Nov 3, 2009, 10:00 am EasternAbout STAAR Surgical (NasdaqGM:STAA)STAAR Surgical Company, together with its subsidiaries, develops, manufactures, and sells intraocular lenses (IOL), implantable collamer lenses (ICL), and ophthalmic surgical products used primarily in cataract and refractive surgery. The company’s IOL products include silicone Toric IOL, which is used in cataract surgery for the treatment of preexisting astigmatism; The Preloaded Injector, a three-piece silicone or acrylic IOL preloaded into a single-use disposable injector; and Aspheric three-piece IOLs that provides a clearer image in low light. Its ICL products comprise the VISIAN ICL and VISIAN Toric ICL for the treatment of refractive disorders, such as myopia, hyperopia, and astigmatism. STAAR Surgical Company’s ophthalmic surgical products consist of STAARVISC II, a viscoelastic material, which is used as a protective lubricant and to maintain the shape of the eye during surgery; Cruise Control, a single-use disposable filter that allows for a faster and cleaner phacoemulsification procedure; and the AquaFlow Collagen Glaucoma Drainage Device, an implantable device used for the surgical treatment of glaucoma. The company also distributes implantable lenses, related surgical equipment, consumables, and other supplies. It sells and markets its products to ophthalmologists and health care providers, including surgical centers, hospitals, managed care providers, health maintenance organizations, group purchasing organizations, and government facilities under the Visian, Collamer, STAARVISC, Elastimide, SonicWAVE, and AquaFlow brand names. STAAR Surgical Company operates in the United States, Switzerland, Japan, and Germany. The company was founded in 1982 and is headquartered in Monrovia, California....
Click here to read the whole Article (external link)

STAAR Surgical Generates $464,000 in Cash from Operations During Third Quarter

MONROVIA, Calif., Nov. 2 /PRNewswire-FirstCall/ -- STAAR Surgical Company (Nasdaq: STAA - News), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that it generated $464,000 in cash from operating activities during the third quarter. The cash generated was the largest amount from operating activities for any quarterly period in the past six years. This achievement was made possible due to continued significant progress in the management of domestic operating expense despite recording over $400,000 in legal expenses during the quarter related to former sales representative litigation, net of approximately $300,000 in estimated insurance recoveries. Third Quarter Financial Highlights CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES (000'S) Q1 2008 Q2 2008 Q3 2008 Q4 2008 Q1 2009 Q2 2009 Q3 2009 -------- ------- ------- ------- ------- ------- ------- ($3,370) ($2,760) (1,107) ($991) ($448) $286 $464 ------- ------- ------ ----- ----- ---- ---- Recent Visian ICL HighlightsRecent Intraocular Lens (IOL) Highlights"Our third quarter performance illustrates the continued successful execution in several areas of our overall strategy," said Barry G. Caldwell, President and CEO. "While we have focused sales resources on higher margin products, and our top line was flat versus year ago levels as a result, we generated ...
Click here to read the whole Article (external link)

STAAR SURGICAL CO Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The matters addressed in this Item 2 that are not historical information constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risks and STAAR can give no assurances that its expectations will prove to be correct. Actual results could differ materially from those described in this report because of numerous factors, many of which are beyond the control of STAAR. We have identified known factors in this report and in our Annual Report on Form 10-K for the fiscal year ended January 2, 2009 under the heading "Risk Factors." STAAR undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this report or to reflect actual outcomes. The following discussion should be read in conjunction with STAAR's interim condensed financial statements and the related notes provided under "Item 1 - Financial Statements" above. Overview STAAR Surgical Company develops, manufactures and sells visual implants and other innovative ophthalmic products to improve or correct the vision of patients with cataracts and refractive conditions. We manufacture products in the U.S., Switzerland and Japan and distribute our products worldwide. Originally incorporated in California in 1982, STAAR Surgical Company reincorporated in Delaware in 1986. Unless the context indicates otherwise "we," "us," the "Company," and "STAAR" refer to STAAR Surgical Company and its consolidated subsidiaries. STAAR Surgical Company, Visian®, Collamer®, STAARVISC®, Elastimide®, nanoFLEXTM, nanoPOINTTM, Epi...
Click here to read the whole Article (external link)

STAAR SURGICAL CO Files SEC form 8-K, Regulation FD Disclosure

Show all filings for STAAR SURGICAL CO | Request a Trial to NEW EDGAR Online Pro Form 8-K for STAAR SURGICAL CO 9-Nov-2009Regulation FD Disclosure Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for t...
Click here to read the whole Article (external link)

STAAR SURGICAL CO Files SEC form 8-K, Results of Operations and Financial Condition

Show all filings for STAAR SURGICAL CO | Request a Trial to NEW EDGAR Online Pro Form 8-K for STAAR SURGICAL CO 6-Nov-2009Results of Operations and Financial Condition Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only...
Click here to read the whole Article (external link)